Organization
Kyowa Kirin Pharmaceutical Development
8 clinical trials
2 abstracts
Clinical trial
An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids ChronicallyStatus: Terminated, Estimated PCD: 2021-11-01
Clinical trial
Prospective Research Based Observational Study of Poteligeo® Experience in the Real World in Adult Patients With Mycosis Fungoides and Sézary SyndromeStatus: Recruiting, Estimated PCD: 2024-09-05
Clinical trial
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European PopulationsStatus: Completed, Estimated PCD: 2019-06-01
Clinical trial
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2023-10-04
Abstract
Use of gender-neutral language in clinical trial protocols in select cancers.Org: University of Kentucky, Lexington, KY, Lexington, MA, Kyowa Kirin Pharmaceutical Development,
Abstract
Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis.Org: King Edward Medical University, Lahore Medical Research Center, Pakistan, King Edward Medical University Pakistan, Jhelum,
Clinical trial
A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With OpioidsStatus: Completed, Estimated PCD: 2021-04-01
Clinical trial
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With Opioid Induced Constipation.Status: Completed, Estimated PCD: 2020-03-05
Clinical trial
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)Status: Completed, Estimated PCD: 2015-08-01
Clinical trial
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal GrowthStatus: Completed, Estimated PCD: 2024-05-22